Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018

Atopic Dermatitis

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Br J Dermatol

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.

doi: 10.1111/bjd.20873

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460

Atopic Dermatitis

Relative efficacy of systemic treatments for atopic dermatitis

J Am Acad Dermatol.

Seger EW, Wechter T, Strowd L, Feldman SR

doi: 10.1016/j.jaad.2018.09.053.

Atopic Dermatitis

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

Br J Dermatol.

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH6, Shumel B

doi: 10.1111/bjd.16156.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460.

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

Atopic Dermatitis

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

J Am Acad Dermatol

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL

doi: 10.1016/j.jaad.2021.04.085

Atopic Dermatitis

Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine

J Eur Acad Dermatol Venereol.

Law Ping Man S, Bouzillé G, Beneton N, Safa G, Dupuy A, Droitcourt C

doi: 10.1111/jdv.14880.

Acne

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies

J Am Acad Dermatol.

Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA

doi: 10.1016/j.jaad.2018.08.020.

Related content

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Relative efficacy of systemic treatments for atopic dermatitis

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies